90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma

Trial Timeline

Dec 1, 2015 โ†’ Nov 1, 2016

About 90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo

90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo is a phase 3 stage product being developed by Cipla for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT02624505. Target conditions include Bronchial Asthma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02624505Phase 3Completed

Competing Products

20 competing products in Bronchial Asthma

See all competitors